Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm (MPN) that
accounts for 10% of pregnancy-associated leukemias. The Philadelphia chromosome …

Tyrosine kinase inhibitors (TKIs) are teratogenic. Chronic myeloid leukemia (CML) is
increasingly identified in younger patients who wish to conceive, the management of CML …

Diagnosing chronic myeloid leukaemia (CML) during pregnancy is rare. Tyrosine kinase
inhibitors (TKIs) have traditionally been contraindicated owing to their teratogenicity …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm defined by the
chromosomal translocation t (9; 22)(q34; q11), which fuses the BCR and ABL genes to …

Since the introduction of tyrosine kinase inhibitors (TKIs) at the beginning of the millennium,
the outlook for patients with chronic myeloid leukemia (CML) has improved remarkably. As …

Methods: In this comprehensive literature review, we systematically examined peer-
reviewed articles published in reputable academic journals. Key Contents and Findings …

Management of pregnant patients with chronic myelogenous leukemia (CML) is challenging.
Some of the factors that need to be considered include stage of pregnancy, disease status …

Although the incidence of chronic myeloid leukaemia (CML) in pregnancy is low, it is
progressively rising. The management strategies for CML patients during pregnancy include …

The success of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid
leukaemia (CML) has resulted in a return to a normal life expectancy for the majority of …

Background: Exposure to TKI has teratogenic effects in animal studies and humans. CML is
being identified in younger patients who need to continue treatment for long periods of time …